HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Free wall rupture following rescue angioplasty and intravenous abciximab for failed thrombolysis.

Abstract
Early thrombolytic therapy reduces the risk of cardiac rupture but delayed thrombolysis may increase this risk, despite improving overall survival. The mechanism appears to be related to both unsuccessful early reperfusion and haemorrhagic transformation following delayed reperfusion. The effect of antiplatelet therapy with glycoprotein IIb-IIIa receptor blockers (abciximab) on cardiac rupture is unknown. It is possible that they may contribute to cardiac rupture by promoting haemorrhagic transformation of the infarcted area. In this report we describe a 57 year old man who underwent emergency coronary angioplasty and stenting following failed thrombolytic therapy for an acute anterior myocardial infarction. A suboptimal result was obtained which necessitated an intravenous bolus of abciximab followed by an infusion. He abruptly developed electromechanical dissociation. Echocardiogram confirmed pericardial tamponade and a pericardial drain was inserted but the patient could not be resuscitated. Postmortem examination confirmed a large transmural rupture of the infarcted anterior wall which had undergone haemorrhagic transformation.
AuthorsK P Balachandran, K G Oldroyd
JournalScottish medical journal (Scott Med J) Vol. 46 Issue 3 Pg. 87-8 (Jun 2001) ISSN: 0036-9330 [Print] Scotland
PMID11501328 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Antibodies, Monoclonal
  • Immunoglobulin Fab Fragments
  • Platelet Aggregation Inhibitors
  • Abciximab
Topics
  • Abciximab
  • Angioplasty, Balloon, Coronary
  • Antibodies, Monoclonal (administration & dosage, adverse effects, therapeutic use)
  • Fatal Outcome
  • Heart Rupture, Post-Infarction (chemically induced)
  • Humans
  • Immunoglobulin Fab Fragments (administration & dosage, adverse effects, therapeutic use)
  • Infusions, Intravenous
  • Male
  • Middle Aged
  • Myocardial Infarction (therapy)
  • Platelet Aggregation Inhibitors (administration & dosage, adverse effects, therapeutic use)
  • Stents
  • Thrombolytic Therapy
  • Treatment Failure

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: